非瓣膜性房颤患者口服抗凝药转换:叙述性综述
本叙述性综述检索PubMed、Scopus和Embase至2020年6月27日,纳入2013年后发表的39篇文章,总结非瓣膜性房颤患者口服抗凝药转换的模式、原因及临床后果。转换在临床实践中常见且随药物类型显著变化,报告转换原因和临床结局的研究相对有限;转换对出血结局的影响不一致,对卒中和其他血栓结局无显著影响。
要点
- 口服抗凝药转换在房颤患者中常见,且随药物类型显著变化。
- 转换决策常与安全性问题(通常为出血)、抗凝控制不佳和易用性相关。
- 转换对卒中和其他血栓结局无显著影响,出血结局证据不一致。
核心结论
- 口服抗凝药转换在临床实践中常见,且随口服抗凝药类型显著变化。
- 报告转换原因和临床结局的研究相对有限。
- 转换对卒中和其他血栓结局无显著影响,出血结局发现不一致。
研究设计与样本
- 叙述性综述,检索PubMed、Scopus和Embase,检索日期为2020年6月27日。
- 纳入2013年后发表的39篇文章,始于阿哌沙班引入之后。
主要发现
- 转换决策常与安全性问题(通常为出血)、抗凝控制不佳和易用性相关。
- 患者特征、临床状况和药物相互作用与口服抗凝药转换相关。
- 转换后出血结局的发现不一致,可能受转换理由和转换方案混杂。
- 转换对卒中和其他血栓结局风险无显著影响。
临床怎么用
- 临床决策转换口服抗凝药时需综合评估安全性问题、抗凝控制和易用性。
- 应关注患者特征、临床状况和药物相互作用对转换的影响。
局限性
- 纳入研究数量有限。
- 纳入研究随访时间相对较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approval of direct-acting oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF) was an important milestone, providing a wider range of treatment options and creating the possibility for drug switching after initiation. In addition to improved utilisation of oral anticoagulants (OACs) for stroke prevention, reports of switching among OACs are growing in the literature; switching may influence clinical outcomes, healthcare costs and patient satisfaction. This review aimed to summarise the current literature on the pattern of OAC switching in patients with AF, including reasons for switching and clinical consequences following switching. A literature search was conducted in PubMed, Scopus and Embase on 27 June 2020. We included 39 articles published after 2013, following the introduction of apixaban. The review found that switching among OACs was common in clinical practice, significantly varying with the type of OAC. Studies reporting the reason for switching and clinical outcomes were comparatively limited. The decision to switch was often related to safety issues (usually bleeding), poor anticoagulation control and ease of use. Patient characteristics, clinical conditions and drug interactions were found to be associated with switching from OACs. Findings regarding bleeding outcomes following switching were inconsistent, possibly confounded by the rationale for switching and the switching protocol. Noting the limited number of studies included and their relatively short follow-up periods, switching did not have a significant impact on the risk of stroke and other thrombotic outcomes. Further prospective studies are needed to understand better potential rationales for switching and the clinical outcomes.
引用
- Kefale AT, Peterson GM, Bezabhe WM, et al. Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review. Br J Clin Pharmacol. 2021. PMID: 34350609. doi:10.1111/bcp.15021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。